---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-003797"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2025-01-27T23:59:59+00:00"
generated_at: "2026-05-27T08:57:13.921662+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences: CMS delays Genetic Testing LCD to April 24, 2025; Company re-evaluates restructuring plan

## Summary
- CMS directed Medicare contractors to delay implementation of LCD L39365 from Feb 23 to April 24, 2025.
- Delay allows Trump administration to review clinical evidence for PancraGEN assay and assess patient impact.
- Interpace will continue offering PancraGEN and re-evaluate its previously announced restructuring plan.
- CEO Burnell stated the company is sustainable without PancraGEN but extension preserves jobs and patient access.
- PancraGEN has been covered by Medicare for over 10 years, helped over 80,000 patients.

## SEC filing metadata
- accession: 0001493152-25-003797
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2025-01-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315225003797/0001493152-25-003797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315225003797/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-003797
- JSON: https://secwatch.observer/filing/0001493152-25-003797.json
- Plain text: https://secwatch.observer/filing/0001493152-25-003797.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.